Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
HIV clinics could lose over $100 million each year—notably those serving Black, brown, queer and Southern communities.
Several formulations of generic Truvada are now available at a lower cost.
Teva’s new version of TDF and emtricitabine doesn’t offer much of a price break, but that could come next spring.
A low-cost generic version of Truvada as PrEP will hit the market September 30.
Fact-checkers and HIV advocates break down the president’s State of the Union boasts.
A new lawsuit accuses the imprisoned hedge funder of blocking generic rivals of an AIDS-related drug.
“This is excellent news for all children living with HIV.”
The FDA has found a probable cancer-causing contaminant in generic drugs shipped from abroad––most recently, Zantac (ranitidine).
At the center of the lawsuit is Teva Pharmaceutical, slated to sell a generic version of the HIV prevention pill PrEP next year.
The head of the Food and Drug Administration cited a long commute and time away from family as reasons to step down.
U.S. activists unveil a national action plan to #BreakThePatent. It points out that taxpayers funded the research behind Truvada as PrEP.
Stocks of drug companies are rising—and that’s not a good sign for consumers.
The FDA commissioner wants drugmakers to “end the shenanigans.”
However, Gilead Sciences, the brand-name manufacturer of Truvada, insists a generic version “will not be immediately available.”
Scott Gottlieb has said he wants lower costs and faster drug approvals.
New HCV treatment boasts over 90 percent cure rates, costs $84,000 for in the United States.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.